

# Sverre E Kjeldsen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8324740/sverre-e-kjeldsen-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

239  
papers

42,932  
citations

66  
h-index

206  
g-index

323  
ext. papers

50,089  
ext. citations

5.2  
avg, IF

6.56  
L-index

#	Paper	IF	Citations
239	Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophy-Application of A New Multivariate Predictive Model. The Life Study.. <i>Reviews in Cardiovascular Medicine</i> , <b>2022</b> , 23, 95	3.9	0
238	Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines.. <i>Hypertension</i> , <b>2022</b> , 101161HYPERTENSIONAHA12219020	8.5	1
237	The Oslo Ischaemia Study: cohort profile. <i>BMJ Open</i> , <b>2021</b> , 11, e049111	3	
236	Attended vs. unattended blood pressure - learnings beyond SPRINT. <i>Blood Pressure</i> , <b>2021</b> , 30, 439-440	1.7	1
235	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 558-570	21.7	15
234	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 1522-1545	1.9	7
233	Novel insights into stroke risk beyond resting and maximal bicycle exercise systolic blood pressure. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 2022-2029	1.9	1
232	Smoking and overweight associated with masked uncontrolled hypertension: a Hypertension Optimal Treatment (HOT) Sub-Study. <i>Blood Pressure</i> , <b>2021</b> , 30, 51-59	1.7	4
231	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. <i>Blood Pressure</i> , <b>2021</b> , 30, 90-97	1.7	2
230	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. <i>Blood Pressure</i> , <b>2021</b> , 30, 82-89	1.7	1
229	Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. <i>Hypertension</i> , <b>2021</b> , 77, 692-705	8.5	28
228	Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective. <i>Hypertension</i> , <b>2021</b> , 78, 555-558	8.5	6
227	Detection of Nonadherence to Antihypertensive Treatment by Measurements of Serum Drug Concentrations. <i>Hypertension</i> , <b>2021</b> , 78, 617-628	8.5	5
226	Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers. <i>Hypertension</i> , <b>2020</b> , 75, 1584-1592	8.5	6
225	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. <i>Circulation</i> , <b>2020</b> , 142, 621-642	16.7	88
224	Eivind Berge, MD, PhD, 1964-2020: Cardiologist Who Was Fighting Stroke. <i>Stroke</i> , <b>2020</b> , 51, 1353-1355	6.7	1
223	On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy. <i>Blood Pressure</i> , <b>2020</b> , 29, 319-326	1.7	0

222	Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning?. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 1396-1406	1.9	9
221	Medical Therapies for Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , <b>2020</b> , 75, 23-32	8.5	25
220	Exercise Systolic Blood Pressure at Moderate Workload Is Linearly Associated With Coronary Disease Risk in Healthy Men. <i>Hypertension</i> , <b>2020</b> , 75, 44-50	8.5	12
219	Assessing hypertension therapies: randomization or confounding by indication?. <i>Nature Reviews Cardiology</i> , <b>2020</b> , 17, 73-74	14.8	0
218	Change in Body Weight and Long-Term Risk of Stroke and Death in Healthy Men. <i>Stroke</i> , <b>2020</b> , 51, 1435-1441	6.4	6
217	Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2019</b> , 5, 122-123	6.4	1
216	Effect of antihypertensive therapy on development of incident conduction system disease in hypertensive patients. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 629-635	1.9	
215	Association of left bundle branch block with new onset abnormal wall motion in treated hypertensive patients with left ventricle hypertrophy: the LIFE Echo Sub-study. <i>Blood Pressure</i> , <b>2019</b> , 28, 84-92	1.7	
214	SBP above 180 mmHg at moderate exercise workload increases coronary heart disease risk in healthy men during 28-year follow-up. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 949-955	1.9	4
213	Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. <i>Blood Pressure</i> , <b>2019</b> , 28, 317-326	1.7	3
212	Which Target Blood Pressure in Year 2018? Evidence from Recent Clinical Trials. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2018</b> , 25, 151-158	2.9	2
211	Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. <i>European Heart Journal</i> , <b>2018</b> , 39, 2243-2251	9.5	109
210	Blood pressure response to renal denervation is correlated with baseline blood pressure variability: a patient-level meta-analysis. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 221-229	1.9	12
209	Long-term predictors of stroke in healthy middle-aged men. <i>International Journal of Stroke</i> , <b>2018</b> , 13, 292-300	6.3	6
208	Final Farewell to Alberto Zanchetti MD. <i>European Heart Journal</i> , <b>2018</b> , 39, 2616-2617	9.5	
207	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , <b>2018</b> , 39, 3021-3104	9.5	3698
206	Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged men. <i>European Journal of Preventive Cardiology</i> , <b>2018</b> , 25, 1655-1663	3.9	20
205	Directly Observed Therapy in Hypertension (DOT-HTN). <i>Updates in Hypertension and Cardiovascular Protection</i> , <b>2018</b> , 57-85	0.1	3

204	Change in Cardiorespiratory Fitness and Risk of Stroke and Death. <i>Stroke</i> , <b>2018</b> , STROKEAHA1180217986.7		20
203	Hypertension and cardiovascular risk: General aspects. <i>Pharmacological Research</i> , <b>2018</b> , 129, 95-99	10.2	171
202	The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 916-923	1.9	3
201	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 2284-2309	1.9	372
200	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Blood Pressure</i> , <b>2018</b> , 27, 314-340	1.7	132
199	Response to letters from Torp-Pedersen and colleagues and de Courson and colleagues. <i>European Heart Journal</i> , <b>2018</b> , 39, 4221	9.5	
198	2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 2284-2309	1.9	1262
197	Optimal Blood Pressure Target in Diabetic and Nondiabetic Hypertensive Patients. <i>Circulation Research</i> , <b>2018</b> , 123, 528-530	15.7	7
196	Take a Blood Pressure Pill or Benefit from Renal Denervation?. <i>European Heart Journal</i> , <b>2018</b> , 39, 3010-3012	1.2	2
195	Take a blood pressure pill or undergo renal denervation?. <i>Lancet, The</i> , <b>2018</b> , 391, 2298-2300	4.0	5
194	The Un-Observed Automated Office Blood Pressure Measurement Technique Used in the SPRINT Study Points to a Standard Target Office Systolic Blood Pressure. <i>Current Hypertension Reports</i> , <b>2017</b> , 19, 3	4.7	15
193	Blood pressure goals in type 2 diabetes-assessing the evidence. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 319-321	18.1	3
192	Exercise systolic blood pressure at moderate workload predicts cardiovascular disease and mortality through 35 years of follow-up in healthy, middle-aged men. <i>Blood Pressure</i> , <b>2017</b> , 26, 229-236	1.7	8
191	Letter by Messerli et al Regarding Article, "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure". <i>Circulation</i> , <b>2017</b> , 135, e45-e46	16.7	6
190	Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. <i>Blood Pressure</i> , <b>2017</b> , 26, 321-331	1.7	17
189	Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. <i>Blood Pressure</i> , <b>2017</b> , 26, 195-203	1.7	21
188	Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	23
187	Relationship between abnormal P-wave terminal force in lead V and left ventricular diastolic dysfunction in hypertensive patients: the LIFE study. <i>Blood Pressure</i> , <b>2017</b> , 26, 94-101	1.7	15

186	From Essential Hypertension to intensive blood pressure lowering: the pros and cons of lower target values. <i>European Heart Journal</i> , <b>2017</b> , 38, 3258-3271	9.5	12
185	A Case for Less Intensive Blood Pressure Control: It Matters to Achieve Target Blood Pressure Early and Sustained Below 140/90mmHg. <i>Progress in Cardiovascular Diseases</i> , <b>2016</b> , 59, 209-218	8.5	9
184	Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. <i>Blood Pressure</i> , <b>2016</b> , 25, 333-336	1.7	24
183	Peter Meredith. <i>Blood Pressure</i> , <b>2016</b> , 25, 129-30	1.7	
182	Impact of achieved systolic blood pressure on renal function in hypertensive patients. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2016</b> , 2, 271-276	4.6	0
181	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. <i>Hypertension</i> , <b>2016</b> , 68, 297-306	8.5	99
180	Heart rate reserve predicts cardiovascular death among physically unfit but otherwise healthy middle-aged men: a 35-year follow-up study. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 59-66	3.9	10
179	Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. <i>Blood Pressure</i> , <b>2016</b> , 25, 235-40	1.7	2
178	Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting. <i>Clinical Drug Investigation</i> , <b>2016</b> , 36, 225-33	3.2	8
177	Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges. <i>Current Hypertension Reports</i> , <b>2016</b> , 18, 6	4.7	28
176	Predictors of abdominal adipose tissue compartments: 18-year follow-up of young men with and without family history of diabetes. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 29, 26-31	3.9	8
175	Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. <i>European Heart Journal</i> , <b>2016</b> , 37, 955-64	9.5	68
174	No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. <i>Blood Pressure</i> , <b>2016</b> , 25, 83-92	1.7	41
173	High blood pressure in US diabetic veterans with normal renal function: a plea for the design of a more powerful and conclusive outcome trial. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 836-7	1.9	
172	Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 1120-9	2.9	2
171	Temporal Reduction in Chronotropic Index Predicts Risk of Cardiovascular Death Among Healthy Middle-Aged Men: a 28-Year Follow-Up Study. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	8
170	Hypertension: When should we treat hypertension in patients with diabetes?. <i>Nature Reviews Cardiology</i> , <b>2016</b> , 13, 252-3	14.8	
169	Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials. <i>Hypertension</i> , <b>2016</b> , 67, 808-12	8.5	148

168	Relationship of diastolic function to new or persistent electrocardiographic left ventricular hypertrophy. <i>Blood Pressure</i> , <b>2016</b> , 25, 364-372	1.7	3
167	Prevention and Treatment of Atrial Fibrillation in Patients with Hypertension <b>2016</b> , 121-136		
166	Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial. <i>Journal of Clinical Hypertension</i> , <b>2015</b> , 17, 141-6	2.3	3
165	High screening blood pressure at young age predicts future masked hypertension: A 17 year follow-up study. <i>Blood Pressure</i> , <b>2015</b> , 24, 131-8	1.7	8
164	Design of renal denervation studies not confounded by antihypertensive drugs. <i>Journal of the American Society of Hypertension</i> , <b>2015</b> , 9, 337-40		5
163	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. <i>Blood Pressure</i> , <b>2015</b> , 24, 263-74	1.7	51
162	Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. <i>Hypertension</i> , <b>2015</b> , 66, 368-73	8.5	49
161	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension. <i>Frontiers in Physiology</i> , <b>2015</b> , 6, 9	4.6	7
160	Long-term survival in the randomized trial of drug treatment in mild to moderate hypertension of the Oslo study 1972-3. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 123-6	3.9	1
159	Physician (investigator) inertia in apparent treatment-resistant hypertension - insights from large randomized clinical trials. Lennart Hansson Memorial Lecture. <i>Blood Pressure</i> , <b>2015</b> , 24, 1-6	1.7	24
158	Systolic Blood Pressure Control and Mortality After Stroke in Hypertensive Patients. <i>Stroke</i> , <b>2015</b> , 46, 2113-8	6.7	12
157	Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. <i>Hypertension</i> , <b>2015</b> , 65, 5-15	8.5	16
156	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2015</b> , 1, 48-56	6.4	6
155	Renal denervation in treatment-resistant hypertension: a reappraisal. <i>Current Opinion in Pharmacology</i> , <b>2015</b> , 21, 48-52	5.1	11
154	Updated national and international hypertension guidelines: a review of current recommendations. <i>Drugs</i> , <b>2014</b> , 74, 2033-51	12.1	72
153	Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 1715-24	2.5	
152	Renal denervation after Symplicity HTN-3: an update. <i>Current Hypertension Reports</i> , <b>2014</b> , 16, 460	4.7	21
151	Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring. <i>Drugs in R and D</i> , <b>2014</b> , 14, 31-43	3.4	13

150	Eligibility for renal denervation: experience at 11 European expert centers. <i>Hypertension</i> , <b>2014</b> , 63, 1319-25	25	55
149	Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment. <i>Blood Pressure</i> , <b>2014</b> , 23, 71-80	1.7	10
148	Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 2488-98; discussion 2498	1.9	12
147	Heart rate as a predictor of stroke in high-risk, hypertensive patients with previous stroke or transient ischemic attack. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2014</b> , 23, 2814-2818	2.8	14
146	Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. <i>Hypertension</i> , <b>2014</b> , 63, 991-9	8.5	156
145	Hyperresponders vs. nonresponder patients after renal denervation: do they differ?. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 2422-7; discussion 2427	1.9	29
144	Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy. <i>American Journal of Hypertension</i> , <b>2014</b> , 27, 966-72	2.3	5
143	Renal Denervation After Symplicity HTN-3 - Back to Basics. Review of the Evidence. <i>European Cardiology Review</i> , <b>2014</b> , 9, 110-114	3.9	2
142	No support for renal denervation in a meta-analysis. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 2029-2030	15.1	4
141	International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 2031-45	15.1	104
140	Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. <i>Hypertension</i> , <b>2013</b> , 62, 526-32	8.5	82
139	Authors' reply to the letter from Dr Wang: troponins after coronary artery bypass grafting: continuous or cut-point approach?. <i>American Heart Journal</i> , <b>2013</b> , 166, e3	4.9	1
138	First-in-man randomized clinical trial of renal denervation for atrial arrhythmia raises concern. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, e445-e446	15.1	10
137	Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2013</b> , 6, 243-51	6.4	44
136	2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , <b>2013</b> , 22, 193-278	287	286
135	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2013</b> , 34, 2159-219	9.5	3400
134	Low heart rates predict incident atrial fibrillation in healthy middle-aged men. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2013</b> , 6, 726-31	6.4	47
133	Seven-year increase in exercise systolic blood pressure at moderate workload predicts long-term risk of coronary heart disease and mortality in healthy middle-aged men. <i>Hypertension</i> , <b>2013</b> , 61, 1134-40	8.5	14

132	2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , <b>2013</b> , 31, 1281-357	1.9	3363
131	Telomere length is associated with ACE I/D polymorphism in hypertensive patients with left ventricular hypertrophy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2013</b> , 14, 227-34	3	8
130	Rapidly upsloping ST-segment on exercise ECG: a marker of reduced coronary heart disease mortality risk. <i>European Journal of Preventive Cardiology</i> , <b>2013</b> , 20, 541-8	3.9	8
129	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , <b>2013</b> , 31, 1925-38	1.9	635
128	Response to Letter by Morris et al regarding article, "Low heart rates predict incident atrial fibrillation in healthy middle-aged men" by Grundvold et al. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2013</b> , 6, e102	6.4	
127	Revisiting the pre-hypertension debate: increasing evidence for treatment--or not?. <i>Blood Pressure</i> , <b>2013</b> , 22, 344	1.7	
126	Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients. <i>Journal of Clinical Hypertension</i> , <b>2013</b> , 15, 380-8	2.3	5
125	An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 673-82	2.5	1
124	Wolfgang Kiowski. <i>Hypertension</i> , <b>2013</b> , 61, 268-269	8.5	0
123	Patients with treatment-resistant hypertension report increased stress and anxiety: a worldwide study. <i>Journal of Hypertension</i> , <b>2013</b> , 31, 610-5; discussion 615	1.9	18
122	Updated ESH position paper on interventional therapy of resistant hypertension. <i>EuroIntervention</i> , <b>2013</b> , 9 Suppl R, R58-66	3.1	54
121	Treatment of hypertension in diabetes: what is the best therapeutic option?. <i>Expert Review of Cardiovascular Therapy</i> , <b>2012</b> , 10, 727-34	2.5	10
120	Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 685-92	3	131
119	Effect of changing heart rate during treatment of hypertension on incidence of heart failure. <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 699-704	3	16
118	Are fixed-dose combination antihypertensives suitable as first-line therapy?. <i>Current Medical Research and Opinion</i> , <b>2012</b> , 28, 1685-97	2.5	23
117	Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. <i>Hypertension</i> , <b>2012</b> , 60, 347-53	8.5	50
116	Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. <i>Hypertension</i> , <b>2012</b> , 59, 198-204	8.5	97
115	Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. <i>Journal of Hypertension</i> , <b>2012</b> , 30, 2213-22	1.9	21



114	Impact of lower achieved blood pressure on outcomes in hypertensive patients. <i>Journal of Hypertension</i> , <b>2012</b> , 30, 802-10; discussion 810	1.9	35
113	Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group on Hypertension Arrhythmias and Thrombosis of the European Society of Hypertension. <i>Journal of Hypertension</i> , <b>2012</b> , 30, 239-52	1.9	138
112	ESH position paper: renal denervation - an interventional therapy of resistant hypertension. <i>Journal of Hypertension</i> , <b>2012</b> , 30, 837-41	1.9	187
111	The role of beta-blockers in the treatment of chronic heart failure. <i>Trends in Pharmacological Sciences</i> , <b>2011</b> , 32, 206-12	13.2	22
110	Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 997-1004	1.9	4
109	Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 384-91	12.3	15
108	All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. <i>European Heart Journal</i> , <b>2010</b> , 31, 2271-9	9.5	71
107	Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 879-87	2.5	4
106	Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2299-307	15.1	306
105	Interaction between inflammation and blood viscosity predicts cardiovascular mortality. <i>Scandinavian Cardiovascular Journal</i> , <b>2010</b> , 44, 107-112	2	16
104	Hypertension and atrial fibrillation with emphasis on prevention. <i>Blood Pressure</i> , <b>2009</b> , 18, 94-8	1.7	2
103	Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). <i>Circulation</i> , <b>2009</b> , 119, 1883-91	16.7	50
102	Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. <i>Blood Pressure</i> , <b>2009</b> , 18, 348-61	1.7	13
101	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , <b>2009</b> , 27, 2121-58	1.9	1004
100	Blood pressure control and components of the metabolic syndrome: the GOOD survey. <i>Cardiovascular Diabetology</i> , <b>2009</b> , 8, 51	8.7	29
99	Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. <i>Journal of Hypertension</i> , <b>2009</b> , 27, 673-9	1.9	45
98	Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study. <i>Journal of Hypertension</i> , <b>2009</b> , 27, 2271-7	1.9	15
97	Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial. <i>Blood Pressure</i> , <b>2008</b> , 17, 170-7	1.7	10

96	Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2008</b> , 1, 337-43	6.4	46
95	Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective. <i>Blood Pressure</i> , <b>2008</b> , 17, 260-9	1.7	7
94	Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 2064-70	1.9	62
93	Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 403-11	1.9	151
92	Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 1244-9	1.9	23
91	Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. <i>Circulation</i> , <b>2007</b> , 116, 700-5	16.7	163
90	Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 311-9	8	89
89	Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. <i>Hypertension</i> , <b>2007</b> , 50, 467-73	8.5	88
88	2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , <b>2007</b> , 25, 1105-87	1.9	3825
87	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , <b>2007</b> , 25, 1751-62	1.9	871
86	Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure. <i>Journal of Hypertension</i> , <b>2007</b> , 25, 15-23	1.9	36
85	Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 259-70	2.5	21
84	Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 299-305	4.4	2
83	Are all the hypertensives made equal?. <i>Herz</i> , <b>2006</b> , 31, 323-30	2.6	4
82	Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 296, 1242-8	27.4	187
81	The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. <i>Hypertension</i> , <b>2006</b> , 48, 385-91	8.5	114
80	Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. <i>Circulation</i> , <b>2006</b> , 113, 67-73	16.7	88
79	Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy. <i>Journal of Clinical Hypertension</i> , <b>2006</b> , 8, 487-92	2.3	17

78	Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. <i>Journal of Hypertension</i> , <b>2006</b> , 24, 1405-12	1.9	119
77	ESH statement on detection and punishment of abstract fraud and poster plagiarism. <i>Journal of Hypertension</i> , <b>2006</b> , 24, 203-4	1.9	
76	Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. <i>Journal of Hypertension</i> , <b>2006</b> , 24, 775-81	1.9	62
75	Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. <i>Journal of Hypertension</i> , <b>2006</b> , 24, 2163-8	1.9	110
74	Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. <i>Lancet, The</i> , <b>2005</b> , 366, 895-906	4.0	2253
73	Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. <i>American Journal of Cardiovascular Drugs</i> , <b>2005</b> , 5, 17-22	4	45
72	The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. <i>Journal of Clinical Hypertension</i> , <b>2005</b> , 7, 152-8	2.3	29
71	Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 705-11	15.1	221
70	Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 712-9	15.1	659
69	Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. <i>Journal of Hypertension</i> , <b>2005</b> , 23, 891-8	1.9	46
68	Prevention of cardiovascular events and diabetes with angiotensin-receptor blockers in hypertension: LIFE, SCOPE, and VALUE. <i>Current Hypertension Reports</i> , <b>2005</b> , 7, 155-7	4.7	4
67	Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. <i>Hypertension</i> , <b>2005</b> , 45, 580-5	8.5	30
66	Valsartan in the treatment of hypertension. <i>Aging Health</i> , <b>2005</b> , 1, 27-36		7
65	Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. <i>Hypertension</i> , <b>2005</b> , 45, 198-202	8.5	436
64	Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Expert Opinion on Emerging Drugs</i> , <b>2005</b> , 10, 729-45	3.7	7
63	Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. <i>Circulation</i> , <b>2005</b> , 111, 1924-31	16.7	34
62	Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. <i>Hypertension</i> , <b>2005</b> , 45, 46-52	8.5	80
61	Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 2343-9	27.4	472

60	Plasma catecholamines, blood pressure responses and perceived stress during mental arithmetic stress in young men. <i>Blood Pressure</i> , <b>2004</b> , 13, 287-94	1.7	19
59	The impact of serum uric acid on cardiovascular outcomes in the LIFE study. <i>Kidney International</i> , <b>2004</b> , 65, 1041-9	9.9	331
58	High screening blood pressure is related to sympathetic nervous system activity and insulin resistance in healthy young men. <i>Blood Pressure</i> , <b>2004</b> , 13, 89-94	1.7	19
57	Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 1047-55	15.1	100
56	Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>American Heart Journal</i> , <b>2004</b> , 148, 747-54	4.9	57
55	P-212: The effect of losartan versus atenolol on carotid atherosclerosis in the common carotid arteries in hypertension. Icarus, a life substudy. <i>American Journal of Hypertension</i> , <b>2004</b> , 17, S111	2.3	
54	Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. <i>Lancet, The</i> , <b>2004</b> , 363, 2022-31	4.0	2112
53	Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. <i>Lancet, The</i> , <b>2004</b> , 363, 2049-51	4.0	472
52	Diuretics in the LIFE study. <i>Lancet, The</i> , <b>2004</b> , 364, 413-414	4.0	10
51	Never mind the quality, feel the width--ALLHAT revisited. <i>Blood Pressure</i> , <b>2004</b> , 13, 330-4	1.7	5
50	Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. <i>Journal of Hypertension</i> , <b>2004</b> , 22, 1805-11	1.9	99
49	Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. <i>Blood Pressure</i> , <b>2004</b> , 13, 376-84	1.7	15
48	Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. <i>Circulation</i> , <b>2003</b> , 108, 684-90	16.7	218
47	Hypertension treatment and stroke prevention. <i>Blood Pressure</i> , <b>2003</b> , 12, 264-8	1.7	6
46	Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. <i>Annals of Internal Medicine</i> , <b>2003</b> , 139, 901-6	8	376
45	Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. <i>Lancet, The</i> , <b>2003</b> , 361, 1149-58	4.0	2873
44	OR-21: Relation of serum uric acid to cardiovascular endpoints in hypertension: the life study. <i>American Journal of Hypertension</i> , <b>2003</b> , 16, A9	2.3	2
43	VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. <i>American Journal of Hypertension</i> , <b>2003</b> , 16, 544-8	2.3	84

42	Losartan. <i>American Journal of Cardiovascular Drugs</i> , <b>2003</b> , 3, 378-379		4
41	Serum Uric Acid and Hemorheology in Borderline Hypertensives and in Subjects with Established Hypertension and Left Ventricular Hypertrophy. <i>Blood Pressure</i> , <b>2003</b> , 12, 104-110	1.7	8
40	Losartan vs Atenolol in Prevention of Stroke and Cardiovascular DiseaseReply. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 289, 701	27.4	
39	Serum Uric Acid and Hemorheology in Borderline Hypertensives and in Subjects with Established Hypertension and Left Ventricular Hypertrophy. <i>Blood Pressure</i> , <b>2003</b> , 12, 104-110	1.7	
38	Comparison of home and office blood pressure in treated hypertensives in the Nordic Diltiazem (NORDIL) Study. <i>Blood Pressure</i> , <b>2002</b> , 11, 371-6	1.7	4
37	Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 1491-8	27.4	306
36	Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study. <i>Journal of Hypertension</i> , <b>2002</b> , 20, 1231-7	1.9	23
35	Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. <i>Journal of Hypertension</i> , <b>2002</b> , 20, 1879-86	1.9	271
34	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <i>Lancet, The</i> , <b>2002</b> , 359, 995-1003	40	4163
33	Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <i>Lancet, The</i> , <b>2002</b> , 359, 1004-10	40	1297
32	1999 WHO/ISH Hypertension Guidelines--highlights & ESH update. <i>Journal of Hypertension</i> , <b>2002</b> , 20, 153-5	1.9	34
31	Polymorphisms in candidate genes for blood pressure regulation in young men with normal or elevated screening blood pressure. <i>Blood Pressure</i> , <b>2001</b> , 10, 92-100	1.7	7
30	Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. <i>Blood Pressure</i> , <b>2001</b> , 10, 190-2	1.7	85
29	Home blood pressure monitoring. Current knowledge and directions for future research. <i>Blood Pressure</i> , <b>2001</b> , 10, 271-87	1.7	38
28	Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. <i>Blood Pressure</i> , <b>2001</b> , 10, 83-91	1.7	73
27	Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. <i>Journal of Hypertension</i> , <b>2001</b> , 19, 1149-59	1.9	99
26	Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. <i>Journal of Hypertension</i> , <b>2001</b> , 19, 1343-8	1.9	66
25	Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. <i>Journal of Hypertension</i> , <b>2000</b> , 18, 629-42	1.9	73

24	Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. <i>Hypertension</i> , <b>2000</b> , 36, 766-73	8.5	84
23	INSIGHT and NORDIL. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study. <i>Lancet, The</i> , <b>2000</b> , 356, 1929-30	4.0	9
22	Insulin sensitivity is related to physical fitness and exercise blood pressure to structural vascular properties in young men. <i>Hypertension</i> , <b>1999</b> , 33, 781-6	8.5	36
21	Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. <i>Hypertension</i> , <b>1998</b> , 31, 1014-20	8.5	55
20	Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. <i>Hypertension</i> , <b>1998</b> , 32, 989-97	8.5	253
19	Relationship between insulin sensitivity and maximal forearm blood flow in young men. <i>Hypertension</i> , <b>1998</b> , 32, 838-43	8.5	54
18	Clustering of coronary risk factors with increasing blood pressure at rest and during exercise. <i>Journal of Hypertension</i> , <b>1998</b> , 16, 19-22	1.9	26
17	Predictors of 7-year changes in exercise blood pressure: effects of smoking, physical fitness and pulmonary function. <i>Journal of Hypertension</i> , <b>1997</b> , 15, 245-9	1.9	30
16	Whole blood viscosity, blood pressure and cardiovascular risk factors in healthy blood donors. <i>Blood Pressure</i> , <b>1997</b> , 6, 161-5	1.7	43
15	Cardiac conduction with diltiazem and beta-blockade combined. A review and report on cases. <i>Blood Pressure</i> , <b>1996</b> , 5, 260-3	1.7	9
14	Effects of increased arterial epinephrine on insulin, glucose and phosphate. <i>Blood Pressure</i> , <b>1996</b> , 5, 27-31.7		18
13	Exercise blood pressure predicts mortality from myocardial infarction. <i>Hypertension</i> , <b>1996</b> , 27, 324-9	8.5	114
12	Effect of dietary counselling on blood pressure and arterial plasma catecholamines in primary hypertension. <i>American Journal of Hypertension</i> , <b>1995</b> , 8, 704-11	2.3	35
11	Insulin resistance and sympathetic nervous system activity in hypertensive and normotensive premenopausal women. <i>Blood Pressure</i> , <b>1995</b> , 4, 287-92	1.7	1
10	Sympathetic nervous system involvement in essential hypertension: increased platelet noradrenaline coincides with decreased beta-adrenoreceptor responsiveness. <i>Blood Pressure</i> , <b>1994</b> , 3, 164-71	1.7	22
9	The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. <i>Blood Pressure</i> , <b>1994</b> , 3, 185-8	1.7	71
8	Evaluation of self-measured home vs. clinic intra-arterial blood pressure. <i>Blood Pressure</i> , <b>1993</b> , 2, 28-34	1.7	17
7	Hemodynamic effects of quinapril, a novel angiotensin-converting enzyme inhibitor. <i>Clinical Pharmacology and Therapeutics</i> , <b>1990</b> , 48, 41-9	6.1	9

6	Effects of beta 1- and beta 2-blockade on blood pressure and sympathetic responses to flight phobia stress. <i>Clinical Pharmacology and Therapeutics</i> , <b>1990</b> , 47, 599-607	6.1	10
5	Long-term pacing in VVI-modes elicit similar sympathetic drive. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>1988</b> , 11, 1114-5	1.6	1
4	Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypertensive patients. The LIFE Study. <i>Exploration of Medicine</i> , 128-138	1.1	0
3	Incident left bundle branch block predicts cardiovascular events and death in hypertensive patients with left ventricular hypertrophy. The LIFE Study. <i>Exploration of Medicine</i> , 149-159	1.1	0
2	Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. <i>Exploration of Medicine</i> , 139-148	1.1	0
1	Development of systolic dysfunction unrelated to myocardial infarction in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. <i>Exploration of Medicine</i> , 160-172	1.1	0